

**S5 Table.** Numbers of arms, participants, and participants with events by safety outcome and drug

<b>Drug: Sulphonylurea +</b>	<b>Number of</b>	<b>Hypoglycemia</b>	<b>Serious adverse event</b>
SGLT-2i	Arms	3	3
	Participants with event	81	76
	Participants	869	869
DPP-4i	Arms	9	9
	Participants with event	187	70
	Participants	1852	1852
GLP-1	Arms	4	3
	Participants with event	170	23
	Participants	1364	669
TZD	Arms	6	1
	Participants with event	221	217
	Participants	2004	508
Met	Arms	2	1
	Participants with event	55	3
	Participants	383	63
AGI	Arms	3	2
	Participants with event	31	21
	Participants	297	238
Basal	Arms	1	1
	Participants with event	23	6
	Participants	79	79
PLA	Arms	19	14
	Participants with event	171	314
	Participants	2638	2057
<b>Total number of</b>			
	<b>Arms</b>	47	34
	<b>Participants with event</b>	939	730
	<b>Participants</b>	9486	6335

Note: SGLT-2i, sodium-glucose co-transporter-2 inhibitor; DPP-4i, dipeptidyl peptidase-4 inhibitor; GLP-1, glucagon-like peptide-1 receptor agonist; AGI,  $\alpha$ -glucosidase inhibitor; TZD, thiazolidinedione; Met, metformin; Basal, basal (long acting) insulin, PLA, placebo.